560 related articles for article (PubMed ID: 28349504)
21. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
22. Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema.
Shimura M; Yasuda K; Minezaki T; Noma H
Jpn J Ophthalmol; 2016 Sep; 60(5):401-7. PubMed ID: 27306783
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial.
Ghanbari H; Kianersi F; Sonbolestan SA; Abtahi MA; Akbari M; Abtahi ZA; Abtahi SH
Int Ophthalmol; 2017 Aug; 37(4):867-874. PubMed ID: 27624173
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.
Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M; Sadrinia V
Middle East Afr J Ophthalmol; 2018; 25(1):1-7. PubMed ID: 29899643
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
26. The effect of combined treatment of bevacizumab and triamcinolone for diabetic macular edema refractory to previous intravitreal mono-injections.
Yolcu Ü; Sobaci G
Int Ophthalmol; 2015 Feb; 35(1):73-9. PubMed ID: 25425105
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
28. Twenty-Four Months Follow-Up of Intravitreal Bevacizumab Injection Versus Intravitreal Triamcinolone Acetonide Injection for the Management of Persistent Non-Infectious Uveitic Cystoid Macular Edema.
Lasave AF; Schlaen A; Zeballos DG; Díaz-Llopis M; Couto C; El-Haig WM; Arevalo JF
Ocul Immunol Inflamm; 2019; 27(2):294-302. PubMed ID: 29157128
[TBL] [Abstract][Full Text] [Related]
29. Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection.
Kim MW; Moon H; Yang SJ; Joe SG
Korean J Ophthalmol; 2016 Feb; 30(1):25-31. PubMed ID: 26865800
[TBL] [Abstract][Full Text] [Related]
30. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study.
Park DH; Shin JP; Kim SY
Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):641-50. PubMed ID: 20012643
[TBL] [Abstract][Full Text] [Related]
32. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion.
Sonoda Y; Arimura N; Shimura M; Sakamoto T
Retina; 2011 Feb; 31(2):290-7. PubMed ID: 21102366
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion.
Demir M; Dirim B; Acar Z; Sendul Y; Oba E
Indian J Ophthalmol; 2014 Mar; 62(3):279-83. PubMed ID: 23571251
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.
Wang YS; Li X; Wang HY; Zhang ZF; Li MH; Su XN
Chin Med J (Engl); 2011 Feb; 124(3):352-8. PubMed ID: 21362332
[TBL] [Abstract][Full Text] [Related]
36. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema.
Cardillo JA; Melo LA; Costa RA; Skaf M; Belfort R; Souza-Filho AA; Farah ME; Kuppermann BD
Ophthalmology; 2005 Sep; 112(9):1557-63. PubMed ID: 16019075
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Ahmadieh H; Nourinia R; Hafezi-Moghadam A; Sabbaghi H; Nakao S; Zandi S; Yaseri M; Tofighi Z; Akbarian S
Br J Ophthalmol; 2019 Jul; 103(7):922-927. PubMed ID: 30150280
[TBL] [Abstract][Full Text] [Related]
38. Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema.
Rahimi M; Shahrzad SS; Banifatemi M
Iran J Immunol; 2012 Jun; 9(2):136-44. PubMed ID: 22735801
[TBL] [Abstract][Full Text] [Related]
39. The variable efficacy of intravitreal bevacizumab and triamcinolone acetonide for cystoid macular edema due to radiation retinopathy.
Bakri SJ; Larson TA
Semin Ophthalmol; 2015 Jul; 30(4):276-80. PubMed ID: 24251435
[TBL] [Abstract][Full Text] [Related]
40. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
